Company Overview

Company name: Zynerba Pharmaceuticals (NAS: ZYNE)
Also known as: Zynerba
Description: Developer of transdermal cannabinoid treatments for patients. The company is developing two therapeutic medicines based on proprietary transdermal technologies that may allow controlled delivery of therapeutic levels of cannabinoids.
Year founded: 2004
Parent company:
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
Employees: 22
City: Devon
State: Pennsylvania
Country: United States
Region: Americas

Financial Highlights

Start up capital raised (USD Million): 108.41
Business status: Profitable
Ownership: Publicly Held
Exchange: NAS
Ticker: ZYNE
Revenue (USD Million): 0.00
Gross profit (USD Million):
Net income (USD Million) -40.24
Enterprise value: 100.70
Earnings before interest, tax, depreciation and amortization (EBITDA): -40.94
Fiscal period: TTM 3Q2018
Financing Status: The company raised $50.4 million in its second public offering on the NASDAQ stock exchange under the ticker symbol of ZYNE on January 19, 2017. A total of 2,800,000 shares were sold at a price of $18 per share. After the offering, there was a total of 12,794,825 outstanding shares (excluding the over-allotment option) priced at $18 per share, valuing the company at $230.3 million. The company intends to use the net proceeds from this offering to continue to fund the clinical development of ZYN002 and ZYN001, for research and development, and for general corporate purposes.
Number of active investors:
Profile last updated: 08-Sep-2018
Last known valuation: 230.31
Last known valuation date: 19-Jan-2017